These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

465 related items for PubMed ID: 27722966

  • 1. Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update.
    Scheen AJ.
    Drug Saf; 2005 Jul; 28(7):601-631. PubMed ID: 27722966
    [Abstract] [Full Text] [Related]

  • 2. Drug interactions of clinical importance with antihyperglycaemic agents: an update.
    Scheen AJ.
    Drug Saf; 2005 Jul; 28(7):601-31. PubMed ID: 15963007
    [Abstract] [Full Text] [Related]

  • 3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL, Figgitt DP.
    Pharmacoeconomics; 2004 Jul; 22(6):389-411. PubMed ID: 15099124
    [Abstract] [Full Text] [Related]

  • 4. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
    Scheen AJ.
    Clin Pharmacokinet; 2007 Jul; 46(2):93-108. PubMed ID: 17253883
    [Abstract] [Full Text] [Related]

  • 5. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
    Scheen AJ.
    Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
    [Abstract] [Full Text] [Related]

  • 6. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ, Bailey CJ.
    Drugs; 2005 Sep; 65(3):385-411. PubMed ID: 15669880
    [Abstract] [Full Text] [Related]

  • 7. Antihyperglycaemic agents. Drug interactions of clinical importance.
    Scheen AJ, Lefèbvre PJ.
    Drug Saf; 1995 Jan; 12(1):32-45. PubMed ID: 7741982
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Management of antidiabetic medications in overdose.
    Spiller HA.
    Drug Saf; 1998 Nov; 19(5):411-24. PubMed ID: 9825953
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
    Hemmingsen B, Schroll JB, Lund SS, Wetterslev J, Gluud C, Vaag A, Sonne DP, Lundstrøm LH, Almdal T.
    Cochrane Database Syst Rev; 2013 Apr 30; (4):CD009008. PubMed ID: 23633364
    [Abstract] [Full Text] [Related]

  • 14. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.
    Culy CR, Jarvis B.
    Drugs; 2001 Apr 30; 61(11):1625-60. PubMed ID: 11577798
    [Abstract] [Full Text] [Related]

  • 15. Glucose-lowering treatment of type 2 diabetes. Part II--Glucose-lowering drugs after metformin: a choice based largely on adverse effects.
    Prescrire Int; 2015 May 30; 24(160):130-5. PubMed ID: 26034806
    [Abstract] [Full Text] [Related]

  • 16. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
    Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmöller J.
    Clin Pharmacokinet; 2005 May 30; 44(12):1209-25. PubMed ID: 16372821
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Rosiglitazone/Metformin.
    Wellington K.
    Drugs; 2005 May 30; 65(11):1581-92; discussion 1593-4. PubMed ID: 16033298
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.